Audit: QRS - Thai Ginseng for Health & Longevity

Audit conducted on 21/08/2026 09:33 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol values, time-to-effect figures, benefit/risk labels, biomarker targets and cadence trace verbatim to ER lines 319–341, 376, 404–425.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	No ER hedging phrase is dropped or altered; the Speculative tiers in Benefits and Risks carry the ER’s own tier assignment.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	ER’s absolute nitrate contraindication stays in the Contraindications gate; PDE5 inhibitors stay in Key Interactions, matching the ER’s “caution rather than contraindication” (ER line 272).
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications derive only from the ER’s “Populations who should avoid” list plus the ER’s absolute-contraindication bullet; no modifying factor appears as a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS carries no PMIDs, citations, expert names, NCT IDs or brand names at all; the ER’s sponsor names were dropped from action_2_sub rather than added.
1.6	The QRS does not introduce new attributions.	🟢	No attribution appears anywhere in the sheet.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	The deflationary, sponsorship-aware framing of the ER Conclusion (lines 451–455) is preserved in at_a_glance.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified protocol and monitoring targets are stated plainly, without alarm or promotion.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Cadence and protocol cells are stated descriptively (“Baseline set before the first capsule”), not as orders.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No prescriptive verbs in the sheet’s own voice; the disclaimer is fixed template text.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrence of “recommend”, “advise”, “should” or “must” in any populated span.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronoun occurs anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms retained are the ER’s own decision-gate drug classes and biomarker names, which item 9.5 requires be preserved; Child-Pugh is glossed inline.
2.8	Information is presented in a concise and very compact manner	🟢	Every list item is a stripped noun phrase; magnitudes, mechanisms and citations are removed.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-file scan for “you/your/we/our”.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional-range targets (fasting insulin below 6 µIU/mL, ALT below 25 U/L) address an optimizing rather than general reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	CT/DEXA visceral-fat scanning and a repeat 4-week liver panel are retained without cost-based softening.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplified “ask your doctor” framing; monitoring assumes self-directed testing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	at_a_glance foregrounds sponsorship bias and the CYP3A4 interaction, the two facts that change the decision for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Cellular longevity signaling” and “skin aging support” are used; “anti-aging” does not occur.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“capsule”, “extract”, “adverse” register throughout; no consumer-grade substitutions.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed strings present verbatim at lines 445, 491, 539, 614, 639, 780, 565, 581, and 643–645; tier labels intact in both Benefits and Risks.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	63 named spans present, forming the complete set: header (4), at_a_glance, action_1–3, time_1–3, benefits (4), stop/caution, risks (4), marker_1–8, monitoring_cadence, qualitative_item_1–5.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The non-variable template spans website="evidence_review", website="full_review" and website="audit" are untouched (lines 423, 426, 439).

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section feeding the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels (“Standard dose”, “Metabolic approach”, “Best time of day”), all nine interaction labels and all five qualitative labels are carried verbatim from the ER’s bold labels.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Biomarker names match the ER table’s Biomarker column exactly; benefit/risk labels match the ER’s #### headings.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Full-file Unicode scan returns no emoji; the ER’s tier emojis and ⚠️ Conflicted markers were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to the per-section budget: magnitudes, mechanisms and citations stripped from Benefits/Risks, trailing em-dash rationales stripped from both gates.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Comment opens at line 2, immediately after <!doctype html> on line 1, and closes at line 14 before any other content.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the preamble text sits on line 2.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in the header, footer or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:02" is quoted, and it contains a colon requiring it.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: thai_ginseng_2026-0825-0725_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5 states 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0821-0922, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the actual filename exactly.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All twelve keys are single-space separated with no stray whitespace or superfluous quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Thai Ginseng for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Thai Ginseng for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421 shows 08/21/2026, matching qrs_creation_date 2026-0821.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only the title and the template subline; the ER’s “Also known as” line was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses ER Conclusion paragraphs 1–3 (lines 451–455) into identity, best-supported effect, tolerability and the two dominant caveats.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Ginger relative (line 451), fat loss over three months as most replicated (453), strength/endurance next (453), mild side effects (453), company funding (455), CYP3A4 clearance blockade (455).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; CYP3A4 is rendered as “the enzyme system clearing most prescription drugs”.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, year or sample size appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	Uses “modest” and “small gains” rather than the ER’s cm² and SMD figures.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All six items map to ER lines 274 and 290–295.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All six ER “Populations who should avoid” entries are present, with the nitrate entry merged with the ER’s absolute-contraindication bullet (line 274).
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Six <li> elements inside the stop_items span (lines 568–576).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER em-dash rationale (“no reproductive-toxicity data”, “the rodent histology signal”, “the only pediatric data…”) is stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“Child-Pugh Class B or C (moderate to severe liver impairment)”, “within 14 days”, “under 18”, the NTI drug list and “without prescriber supervision” are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names six such populations and the section is correctly populated, not empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items map to ER lines 268–286.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Nine of the ER’s ten interaction bullets appear; the nitrate bullet is correctly excluded because it sits in the Contraindications gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Nine <li> elements inside the caution_items span (lines 584–604).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s “Caution;”/”Monitor;” rationales and mitigation sentences are all stripped; only the label and drug list remain.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every ER parenthetical drug list is preserved intact, including the nine CYP3A4 substrates and the Panax ginseng italicization.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names ten interactions and the section is correctly populated, not empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells map to ER Therapeutic Protocol lines 319, 321 and 327.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Standard dose, the 12-week metabolic protocol and dose timing are the three decision-bearing aspects; the remaining ER bullets are qualifiers rather than actions.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies well over three actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry ER-derived content; none is empty or placeholder.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Abdominal fat, physical fitness and sexual function are the three named in the ER’s “Time to effect” bullet (line 376).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Abdominal fat and physical fitness are the two ER High-tier benefits, in ER order of replication; sexual function is Medium tier and comes last.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER names three distinct time-to-effect aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Values 8–12 weeks, 8 weeks and 30 days match ER line 376; subs draw on ER lines 376 and 323.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All six benefit labels map to the #### headings at ER lines 146, 152, 160, 166, 174, 182 and 186.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated (lines 541–557).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Only the ER heading text is carried; the ER’s ⚠️ Conflicted markers and all Magnitude lines are stripped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content appears in any benefit item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All six risk labels map to the #### headings at ER lines 214, 222, 230, 236, 244 and 248.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated (lines 616–632).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	The ER’s Magnitude figures (Ki 78.14 µg/mL, 60–65% AUC fall, 2/38 vs 1/38) are all omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content appears in any risk item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	All eight rows reproduce the ER Monitoring Protocol & Defining Success table (lines 410–417).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eight ER biomarkers present: waist circumference, visceral fat area, fasting glucose, fasting insulin/HOMA-IR, triglycerides, ALT/AST/GGT, blood pressure and resting heart rate, total and free testosterone.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 770–774 reproduce the ER’s baseline / 4-week / 12-week / 6-month schedule (ER lines 404 and 406).

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All five items map to the ER’s qualitative-marker list at lines 421–425.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five present: erectile-function score, training output, perceived exertion and recovery, waistband fit, afternoon energy and alertness.

Issues 21/08/2026 09:33

Pass rate 100.00%. No issues found.

Issues 21/08/2026 09:30

1. 2.8 — Time-to-effect subs restate their own cells: Each of [time_1_sub] (line 504), [time_2_sub] (line 518) and [time_3_sub] (line 532) opens by repeating the label and value already shown directly above it, spending roughly half the sub text on information the cell has already stated.

Fixes 21/08/2026 09:30

1. 2.8 — Time-to-effect subs restate their own cells: Rewrote all three Time-to-effect subs to drop the opening restatement of their own label and value — [time_1_sub] to “Judging the result earlier than 12 weeks is premature.”, [time_2_sub] to “Energy expenditure itself rises within 60 minutes of a single dose.”, and [time_3_sub] to “Reported on the 100 mg daily protocol.” Each now carries only the information the cell above it does not already show.